Appendix 2 TEMPLATE Mrylan Pharma LLC													
Date of publication: 28/05/2028 2023 HCP/INC Disclosure Report													
	Full Name (Sub-clause 7.1.1)	HCPs: inhabited localities of Principal Practice HCOs: inhabited localities where registered (Clause 7.3)	Country of Principal Practice	Principal Practice Address (Clause 7.3)	Unique country identifier OPTIONAL (Clause 7-3)	Donations and Grants to HCOs (Clause 7.3.2)	Contribution to costs of Events (Sub-clause 7.3.2)			Fee for service and consultancy (Sub-clause 7.3.2 & 7.3.3)			
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		TOTAL OPTIONAL

						N/A	N/A						
ş	OTHER, NOT INCLUDED ABO on an individual basis for le		nnot be disclosed										
	Aggregate amount attributable to transfers of value to such Recipients - Sub-clause 7.3.4												
	Number of Recipients in aggregate disclosure - Sub-clause 7.3.4												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Sub-clause 7.3.4						N/A	0%	0%	0%	0%		
	BROPPILLA NAMED OSCIDIRE - one her per HO () a. all transfers during a year for an individual HO (will be summed up, itemization should be a vailibable for the individual Recipient or public subhorition' consultation only, as paperpoint ()												
HG0s	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients – Sub-clause 7.3.4												
	Number of Recipients in aggregate disclosure - Sub-clause 7.3.4												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Sub-clause 7.3.4					0%	0%	0%	0%	0%	0%		
8 0	AGGREGATT DISCLOSURE												
ũ	Transfers of Value re Research & Development as defined Transfers of Value re Research & Development as defined (Sub-clause 7.3.5)												81209825,80